Clinical TrailsInsmed’s Brensocatib Misses Endpoints in Phase 2b BiRCh Trial for Chronic... Insmed’s Brensocatib Misses Endpoints in Phase 2b BiRCh Trial for Chronic... Read Post »
Clinical TrailsPhase II FALKON Trial Discontinued After Fidrisertib Fails in FOP Phase II FALKON Trial Discontinued After Fidrisertib Fails in FOP Read Post »
Clinical TrailsLilly’s Orforglipron Maintains Weight Loss Post-Wegovy/Zepbound in AT... Lilly’s Orforglipron Maintains Weight Loss Post-Wegovy/Zepbound in AT... Read Post »
Clinical TrailsTakeda’s Zasocitinib Hits All Phase 3 Endpoints in Plaque Psoriasis: ... Takeda’s Zasocitinib Hits All Phase 3 Endpoints in Plaque Psoriasis: ... Read Post »
Clinical TrailsPhase 3 ARTISTRY-2 Data Support Bictegravir–Lenacapavir as a Potential Ne... Phase 3 ARTISTRY-2 Data Support Bictegravir–Lenacapavir as a Potential Ne... Read Post »
Clinical TrailsFDA Awards National Priority Voucher to Teclistamab Plus Daratumumab as Pha... FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab as Pha... Read Post »
Clinical TrailsMazdutide Shows Strong Weight Loss and Metabolic Benefits in Phase 1b Trial... Mazdutide Shows Strong Weight Loss and Metabolic Benefits in Phase 1b Trial... Read Post »
Clinical TrailsAmneal’s Interim Phase 4 ELEVATE-PD Data Shows Extended “Good On”... Amneal’s Interim Phase 4 ELEVATE-PD Data Shows Extended “Good On”... Read Post »
Clinical TrailsEli Lilly’s Triple Agonist Retatrutide Hits Phase 3 Goals in Obesity ... Eli Lilly’s Triple Agonist Retatrutide Hits Phase 3 Goals in Obesity ... Read Post »
Clinical TrailsVertex CASGEVY Breakthrough: First Data in Children 5-11 at ASH 2025, Globa... Vertex CASGEVY Breakthrough: First Data in Children 5-11 at ASH 2025, Globa... Read Post »
Clinical TrailsBreakthrough Rusfertide Phase 3 VERIFY Results: 52-Week Hematocrit Control ... Breakthrough Rusfertide Phase 3 VERIFY Results: 52-Week Hematocrit Control ... Read Post »
Clinical TrailsPfizer’s HYMPAVZI Shows 93% Bleed Reduction in Hemophilia A/B with Inhibi... Pfizer’s HYMPAVZI Shows 93% Bleed Reduction in Hemophilia A/B with Inhibi... Read Post »
Clinical TrailsZorevunersen Four-Year Results Confirm Disease-Modifying Potential in Pedia... Zorevunersen Four-Year Results Confirm Disease-Modifying Potential in Pedia... Read Post »
Clinical TrailsJnJ’s INLEXZO™ Achieves 74% One-Year Disease-Free Survival in BCG-U... JnJ’s INLEXZO™ Achieves 74% One-Year Disease-Free Survival in BCG-U... Read Post »
Clinical TrailsBayer Launches Phase III SUNFLOWER Trial: Mirena 52mg LNG-IUS for Nonatypic... Bayer Launches Phase III SUNFLOWER Trial: Mirena 52mg LNG-IUS for Nonatypic... Read Post »
Clinical TrailsPositive HOPE-3 Phase 3 Results Support Deramiocel as a Potential New Treat... Positive HOPE-3 Phase 3 Results Support Deramiocel as a Potential New Treat... Read Post »
Clinical Trails New Drug ApprovalIonis’ Zilganersen Earns FDA Breakthrough Therapy Designation for Ultra R... Ionis’ Zilganersen Earns FDA Breakthrough Therapy Designation for Ultra R... Read Post »
Clinical TrailsLEQEMBI® (Lecanemab-irmb) CTAD 2025 Data Confirms Aβ Protofibril Reductio... LEQEMBI® (Lecanemab-irmb) CTAD 2025 Data Confirms Aβ Protofibril Reductio... Read Post »
Clinical TrailsEisai Unveils Breakthrough Etalanetug Data at CTAD 2025: Significant Reduct... Eisai Unveils Breakthrough Etalanetug Data at CTAD 2025: Significant Reduct... Read Post »
Clinical TrailsMerck Presents Promising First-in-Human Data for Alzheimer’s Candidates M... Merck Presents Promising First-in-Human Data for Alzheimer’s Candidates M... Read Post »
Clinical TrailsAbbVie’s Phase 3 ECLIPSE Study Shows Atogepant (AQUIPTA®) Superior t... AbbVie’s Phase 3 ECLIPSE Study Shows Atogepant (AQUIPTA®) Superior t... Read Post »
Clinical TrailsOral Mosnodenvir Pill’s Rocky Road: 60% Dengue Success in Phase 2a Tr... Oral Mosnodenvir Pill’s Rocky Road: 60% Dengue Success in Phase 2a Tr... Read Post »
Clinical Trails Health TidingsAlexion Advances ALXN2420 to Phase 2: PeptiDream Unlocks Acromegaly Milesto... Alexion Advances ALXN2420 to Phase 2: PeptiDream Unlocks Acromegaly Milesto... Read Post »
Clinical Trails New Drug ApprovalNovo Nordisk Files FDA sNDA for Wegovy 7.2 mg Higher Dose After 20.7% Weigh... Novo Nordisk Files FDA sNDA for Wegovy 7.2 mg Higher Dose After 20.7% Weigh... Read Post »
Clinical TrailsSarepta Receives FDA Approval to Begin ENDEAVOR Cohort 8 Investigating Enha... Sarepta Receives FDA Approval to Begin ENDEAVOR Cohort 8 Investigating Enha... Read Post »
Clinical TrailsNovo Nordisk’s Amycretin Phase 2 Trial Shows Up to 14.5% Weight Loss and ... Novo Nordisk’s Amycretin Phase 2 Trial Shows Up to 14.5% Weight Loss and ... Read Post »
Clinical TrailsJohnson & Johnson’s Posdinemab Fails to Meet Primary Endpoint in Auτ... Johnson & Johnson’s Posdinemab Fails to Meet Primary Endpoint in Auτ... Read Post »
Clinical TrailsKyowa Kirin Launches Phase 3 AOBA Study of KK8398 (Infigratinib) for Achond... Kyowa Kirin Launches Phase 3 AOBA Study of KK8398 (Infigratinib) for Achond... Read Post »
Clinical TrailsSarepta’s SRP-1003 siRNA Program Hits Key Enrollment Milestone, Triggers ... Sarepta’s SRP-1003 siRNA Program Hits Key Enrollment Milestone, Triggers ... Read Post »
Clinical TrailsNovo Nordisk’s Evoke Phase 3 Trial Fails to Show Semaglutide Benefit in A... Novo Nordisk’s Evoke Phase 3 Trial Fails to Show Semaglutide Benefit in A... Read Post »
Clinical TrailsNew Hope for Stroke Survivors: Bayer’s Asundexian Shows Promise in Reduci... New Hope for Stroke Survivors: Bayer’s Asundexian Shows Promise in Reduci... Read Post »
Clinical TrailsPfizer’s Next-Gen mRNA Flu Shot: A New Standard in Vaccine Innovation Pfizer’s Next-Gen mRNA Flu Shot: A New Standard in Vaccine Innovation Read Post »
Clinical TrailsAgios’ Mitapivat Delivers Positive Hemoglobin Gains but Mixed Pain‑Cr... Agios’ Mitapivat Delivers Positive Hemoglobin Gains but Mixed Pain‑Cr... Read Post »
Clinical TrailsMerck Announces Positive Topline Results from Pivotal Phase 3 Trial of Dora... Merck Announces Positive Topline Results from Pivotal Phase 3 Trial of Dora... Read Post »
Clinical TrailsNovo Nordisk’s Wegovy® (Semaglutide 2.4 mg) Delivers Liver Health Benefi... Novo Nordisk’s Wegovy® (Semaglutide 2.4 mg) Delivers Liver Health Benefi... Read Post »
Clinical TrailsLibrexia ACS Trial Ends Early as Efficacy Endpoint Not Met, BMS and J&J... Librexia ACS Trial Ends Early as Efficacy Endpoint Not Met, BMS and J&J... Read Post »
Clinical TrailsWINREVAIR Shows Promising Phase 2 Results in CpcPH with HFpEF WINREVAIR Shows Promising Phase 2 Results in CpcPH with HFpEF Read Post »
Clinical TrailsJohnson & Johnson’s TREMFYA® Confirms Unique Joint Protection in Pso... Johnson & Johnson’s TREMFYA® Confirms Unique Joint Protection in Pso... Read Post »
Clinical TrailsHow AUSTEDO and AUSTEDO XR Improve Quality of Life in Tardive Dyskinesia Pa... How AUSTEDO and AUSTEDO XR Improve Quality of Life in Tardive Dyskinesia Pa... Read Post »
Clinical TrailsVir Biotechnology’s Tobevibart & Elebsiran Combo Achieves Breakth... Vir Biotechnology’s Tobevibart & Elebsiran Combo Achieves Breakth... Read Post »
Clinical TrailsVertex Shows Promising Phase 1/2 Data for Povetacicept in IgA Nephropathy a... Vertex Shows Promising Phase 1/2 Data for Povetacicept in IgA Nephropathy a... Read Post »
Clinical TrailsGilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacap... Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacap... Read Post »
Clinical TrailsRegeneron Factor XI Antibodies Show Superior Efficacy for VTE Prevention... Regeneron Factor XI Antibodies Show Superior Efficacy for VTE Prevention... Read Post »
Clinical TrailsAmgen’s Repatha® Slashes First Major Cardiovascular Events Risk by 25% i... Amgen’s Repatha® Slashes First Major Cardiovascular Events Risk by 25% i... Read Post »
Clinical TrailsLivdelzi® (Seladelpar) Achieves New Milestone in PBC: Phase 3 Data Show La... Livdelzi® (Seladelpar) Achieves New Milestone in PBC: Phase 3 Data Show La... Read Post »
Clinical TrailsGanaplacide’s Innovative Discovery from 2.3 Million Molecules Yields ... Ganaplacide’s Innovative Discovery from 2.3 Million Molecules Yields ... Read Post »
Clinical TrailsAstraZeneca Baxdrostat Shows Breakthrough 14 mmHg 24-Hour Blood Pressure Re... AstraZeneca Baxdrostat Shows Breakthrough 14 mmHg 24-Hour Blood Pressure Re... Read Post »
Clinical TrailsHope for AFRS Sufferers: Dupixent’s Powerful Phase 3 Outcome Hope for AFRS Sufferers: Dupixent’s Powerful Phase 3 Outcome Read Post »
Clinical TrailsBayer’s Finerenone Significantly Reduces UACR in Adults with Chronic ... Bayer’s Finerenone Significantly Reduces UACR in Adults with Chronic ... Read Post »
Clinical TrailsFirst Oral PCSK9 Inhibitor from Merck Cuts LDL Cholesterol by 59% in HeFH P... First Oral PCSK9 Inhibitor from Merck Cuts LDL Cholesterol by 59% in HeFH P... Read Post »
